Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
|Articles|January 1, 2001
The American Journal of Managed Care
- January 2001
- Volume 7
- Issue 1
Drugs and the Elderly, Part 2: Strategies for Improving Prescribing in a Managed Care Environment
Advertisement
Articles in this issue
almost 26 years ago
Indirect Cost of Ischemic Heart Disease to Employersalmost 26 years ago
Disenrollment from Medicare HMOsalmost 26 years ago
A Comparison of Abciximab Use in MCO and Non-MCO Populationsalmost 26 years ago
The Employer's Perspectivealmost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?almost 26 years ago
Is the Healthcare Workforce a Barrier to Cost Containment?Advertisement
Related to this article
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
Health Equity & Access Weekly Roundup: November 6, 2026
4
GLP-1 RAs Improve MASLD, MASH Markers, but Long-Term Benefits Unclear
5